Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Cancer Discovery|2024Cited by 30
Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotypePallavi Galera, Wenbin Xiao, Deepika Dilip et al.|Blood|2025Cited by 9
Supplementary Table S4 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Unknown|2024Cited by 0
Supplementary Figure S3 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Unknown|2024Cited by 0
Supplementary Table S2 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew Dunbar, Ross L. Levine, Robert L. Bowman et al.|Unknown|2024Cited by 0